Deep Venous Thrombosis (DVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Deep Venous Thrombosis (DVT) Market Outlook

Thelansis’s “Deep Venous Thrombosis (DVT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Deep Venous Thrombosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Deep Venous Thrombosis (DVT) Overview

Deep Venous Thrombosis (DVT) is a pathological condition characterized by the obstruction of veins due to hindered venous reflux. It predominantly affects the lower limb venous system, originating from clot formation in a deep calf vein and extending proximally. DVT and venous thromboembolism (VTE) significantly contribute to cardiovascular disease mortality, ranking third after heart attacks and strokes. Various risk factors contribute to the development of DVT, including reduced blood flow, increased venous pressure, mechanical injury to the vein, and elevated blood viscosity. Established causes of DVT and VTE include obesity, pregnancy, advanced age (above 60), surgery, critical care admission, dehydration, and cancer. According to Virchow's triad, the main pathophysiological mechanisms involved in DVT are damage to the vessel wall, blood flow turbulence, and hypercoagulability. Deep veins, as categorized by the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification, include the inferior vena cava, common iliac, internal and external iliac, pelvic veins (including gonadal and broad ligament veins), common femoral, deep femoral vein, femoral, popliteal, paired crural veins of anterior and posterior tibial and peroneal, and muscular veins of gastrocnemial and soleal. The severity of DVT is classified into provoked and unprovoked cases. Provoked DVT occurs due to acquired conditions such as surgery, oral contraceptive use, trauma, immobility, obesity, and cancer. Unprovoked DVT has idiopathic or endogenous causes and carries a higher risk of recurrence if anticoagulation treatment is discontinued. DVT can be further categorized as proximal (above the knee, affecting the femoral or iliofemoral veins) or distal (below the knee). The primary complications associated with DVT are pulmonary embolism (including paradoxical emboli in the presence of an atrial septal defect), post-thrombotic syndrome, and bleeding from anticoagulant medications.

• In the United States, over 200,000 individuals develop venous thrombosis annually, with approximately 50,000 cases complicated by pulmonary embolism.
• Venous thromboembolism, encompassing DVT and pulmonary embolism, occurs in approximately 1 to 2 individuals per 1000 annually in the United States, corresponding to an estimated 300,000 to 600,000 events annually. 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: